Stallmach Andreas, Reuken Philipp A, Grunert Philip, Teich Niels
Klinik für Innere Medizin IV, Universitatsklinikum Jena, Jena, Germany.
Internistische Gemeinschaftspraxis für Verdauungs- und Stoffwechselkrankheiten, Leipzig, Germany.
Z Gastroenterol. 2022 Dec;60(12):1795-1801. doi: 10.1055/a-1744-6697. Epub 2022 Feb 11.
The COVID-19 pandemic is significantly affecting the lives of patients with inflammatory bowel disease (IBD). Those affected and their relatives have numerous questions about the risk of the disease, the course of a possible SARS-CoV-2 infection or the influence of CED-specific therapy on these. Many IBD patients also have additional questions about the safety and effectiveness of a vaccination against SARS-CoV-2. The aim of this review is to summarize the latest findings on COVID-19 and IBD, but also to discuss vaccine response (humoral/cellular), the influence of ongoing therapy on the vaccine response as well as the frequency of side effects and the importance of booster immunizations and to create an evidence-based basis for discussion with patients.
新冠疫情正在显著影响炎症性肠病（IBD）患者的生活。这些患者及其亲属对该疾病的风险、可能感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的病程或IBD特异性治疗对其的影响有诸多疑问。许多IBD患者还对SARS-CoV-2疫苗接种的安全性和有效性有其他疑问。本综述的目的是总结关于新冠病毒和IBD的最新研究结果，同时讨论疫苗反应（体液/细胞）、正在进行的治疗对疫苗反应的影响以及副作用的发生率、加强免疫的重要性，并为与患者的讨论建立循证基础。
